Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in investor meetings at ...

Washington-based Vanda Pharmaceuticals has announced a deal to be the new jersey patch sponsor of Women’s National Basketball ...

Analysts have given Lexicon Pharmaceuticals a total of 5 ratings, with the consensus rating being Buy. The average one-year ...

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for milsaperidone (Bysanti™) for the treatment of acute ...

Fanapt® Q1 2025 total prescriptions (TRx) increased 14% compared to Q1 2024 Fanapt® Q1 2025 new to brand prescriptions (NBRx) increased nearly threefold compared to Q1 2024 Bysanti ...

CFO Kevin Moran reported Q1 2025 revenues of $50 million, a 5% increase year-over-year, attributed to Fanapt’s growth. Fanapt net product sales were $23.5 million, and HETLIOZ sales were $20.9 million ...

The Washington Capitals announced additional initiatives for the Eastern Conference Second Round of the Stanley Cup Playoffs ...

WASHINGTON (AP) — WASHINGTON (AP) — Vanda Pharmaceuticals Inc. (VNDA) on Wednesday reported a loss of $29.5 million in its first quarter. On a per-share basis, the Washington-based company said it had ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ...

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that two poster presentations on investigational ND0612 in Parkinson's disease (PD) will be shared at the 30th World Congress on Parkinson ...

The FDA has accepted the new drug application for the antipsychotic Bysanti and set a goal date for February 21, 2026.

Vanda Pharmaceuticals (NASDAQ:VNDA) is scheduled to announce Q1 earnings results on Wednesday, May 7th, after market close.